PL377680A1 - Pochodne fosfonooksychinazoliny oraz ich zastosowanie farmaceutyczne - Google Patents

Pochodne fosfonooksychinazoliny oraz ich zastosowanie farmaceutyczne

Info

Publication number
PL377680A1
PL377680A1 PL377680A PL37768003A PL377680A1 PL 377680 A1 PL377680 A1 PL 377680A1 PL 377680 A PL377680 A PL 377680A PL 37768003 A PL37768003 A PL 37768003A PL 377680 A1 PL377680 A1 PL 377680A1
Authority
PL
Poland
Prior art keywords
pharmaceutical use
quinazoline derivatives
phosphonooxy
phosphonooxy quinazoline
derivatives
Prior art date
Application number
PL377680A
Other languages
English (en)
Other versions
PL221490B1 (pl
Inventor
Nicola Murdoch Heron
Frederic Henri Jung
Georges Rene Pasquet
Andrew Austen Mortlock
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL377680A1 publication Critical patent/PL377680A1/pl
Publication of PL221490B1 publication Critical patent/PL221490B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL377680A 2002-12-24 2003-12-22 Pochodne fosfonooksychinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania PL221490B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP03291315 2003-06-02

Publications (2)

Publication Number Publication Date
PL377680A1 true PL377680A1 (pl) 2006-02-06
PL221490B1 PL221490B1 (pl) 2016-04-29

Family

ID=32683824

Family Applications (2)

Application Number Title Priority Date Filing Date
PL377680A PL221490B1 (pl) 2002-12-24 2003-12-22 Pochodne fosfonooksychinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
PL412704A PL223998B1 (pl) 2002-12-24 2003-12-22 N-(3-Fluorofenylo)-2-{3-[(7-{3-[etylo(2-hydroksyetylo)amino]propoksy}chinazolin-4-ylo)amino]-1H-pirazol-5-ilo} acetamid oraz jego kompozycja farmaceutyczna

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL412704A PL223998B1 (pl) 2002-12-24 2003-12-22 N-(3-Fluorofenylo)-2-{3-[(7-{3-[etylo(2-hydroksyetylo)amino]propoksy}chinazolin-4-ylo)amino]-1H-pirazol-5-ilo} acetamid oraz jego kompozycja farmaceutyczna

Country Status (29)

Country Link
US (4) US7528121B2 (pl)
EP (2) EP1847539B1 (pl)
JP (3) JP4422102B2 (pl)
KR (1) KR101010299B1 (pl)
AR (2) AR042668A1 (pl)
AT (2) ATE438644T1 (pl)
AU (1) AU2003290313B2 (pl)
BR (1) BRPI0317717B8 (pl)
CA (1) CA2511613C (pl)
CL (1) CL2003002731A1 (pl)
CY (2) CY1107775T1 (pl)
DE (2) DE60328735D1 (pl)
DK (2) DK1847539T3 (pl)
ES (2) ES2329623T3 (pl)
IL (2) IL169112A (pl)
IS (2) IS2504B (pl)
MX (1) MXPA05006918A (pl)
MY (2) MY147761A (pl)
NO (2) NO335193B1 (pl)
NZ (1) NZ540698A (pl)
PL (2) PL221490B1 (pl)
PT (2) PT1847539E (pl)
RU (3) RU2350611C1 (pl)
SA (1) SA04240504B1 (pl)
SI (2) SI1578755T1 (pl)
TW (2) TWI393710B (pl)
UA (1) UA83814C2 (pl)
UY (1) UY28149A1 (pl)
WO (1) WO2004058781A1 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333702T3 (es) * 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
US7407946B2 (en) * 2002-12-24 2008-08-05 Astrazeneca Ab Quinazoline compounds
PT1847539E (pt) * 2002-12-24 2009-10-06 Astrazeneca Ab Derivados de quinazolina
WO2004094410A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Chemical compounds
JP4939220B2 (ja) * 2003-05-15 2012-05-23 アークル インコーポレイテッド ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
EP1802608A1 (en) * 2004-10-12 2007-07-04 AstraZeneca AB Quinazoline derivatives for use against cancer
AU2005293336B2 (en) * 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006044869A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
WO2009111028A1 (en) * 2008-03-04 2009-09-11 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
CA2722220C (en) 2008-04-30 2016-06-07 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
KR20110025856A (ko) * 2008-07-03 2011-03-11 메르크 파텐트 게엠베하 오로라 키나아제 억제제로서 나프티리디니논
CA2744713A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. Raf inhibitors and their uses
KR101849059B1 (ko) 2008-12-11 2018-04-13 악센투아 파마슈투칼스 아베 제니스테인의 결정성 형태
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
KR101940340B1 (ko) 2011-03-04 2019-01-18 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 키나제 억제제로서의 아미노-퀴놀린
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015019624A2 (pt) * 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolinas como inibidores de quinase
DK3046584T3 (en) 2013-09-16 2017-10-02 Astrazeneca Ab THERAPEUTIC POLYMER NANOPARTICLES AND PROCEDURES FOR PREPARING AND USING THEREOF
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
MX2020002646A (es) 2017-09-08 2020-09-25 Univ Leland Stanford Junior Inhibidores de enpp1 y su uso para el tratamiento del cancer.
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1995033724A1 (en) 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (pl) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5962312A (en) 1995-12-18 1999-10-05 Sugen, Inc. Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
DK1119567T3 (da) * 1998-10-08 2005-07-25 Astrazeneca Ab Quinazolinderivater
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CN1391562A (zh) 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
EE200200715A (et) * 2000-06-28 2004-08-16 Astrazeneca Ab Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
EP2277877A1 (en) * 2000-08-18 2011-01-26 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1408980A4 (en) * 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
ES2333702T3 (es) * 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
US7407946B2 (en) * 2002-12-24 2008-08-05 Astrazeneca Ab Quinazoline compounds
PT1847539E (pt) * 2002-12-24 2009-10-06 Astrazeneca Ab Derivados de quinazolina
WO2004094410A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
HK1080481A1 (en) 2006-04-28
US8268841B2 (en) 2012-09-18
TW201102369A (en) 2011-01-16
US20150307534A1 (en) 2015-10-29
NO20131444L (no) 2005-08-03
JP4422102B2 (ja) 2010-02-24
DE60315892T2 (de) 2008-08-14
IS7948A (is) 2005-07-20
EP1847539A1 (en) 2007-10-24
IL185176A0 (en) 2007-12-03
HK1111417A1 (en) 2008-08-08
CY1109479T1 (el) 2014-08-13
RU2350611C1 (ru) 2009-03-27
TWI393710B (zh) 2013-04-21
NO335446B1 (no) 2014-12-15
UA83814C2 (ru) 2008-08-26
NZ540698A (en) 2008-05-30
US9018191B2 (en) 2015-04-28
BRPI0317717B8 (pt) 2021-05-25
US20100069412A1 (en) 2010-03-18
IS2504B (is) 2009-04-15
IL169112A0 (en) 2009-02-11
BR0317717A (pt) 2005-11-22
AR042668A1 (es) 2005-06-29
AR057753A2 (es) 2007-12-19
US20060116357A1 (en) 2006-06-01
US7528121B2 (en) 2009-05-05
SA04240504A (ar) 2005-12-03
SI1847539T1 (sl) 2010-01-29
SI1578755T1 (sl) 2007-12-31
IS8714A (is) 2008-02-13
MY147761A (en) 2013-01-31
US20140162984A1 (en) 2014-06-12
JP4503090B2 (ja) 2010-07-14
DE60328735D1 (de) 2009-09-17
TW200510342A (en) 2005-03-16
MY136174A (en) 2008-08-29
TWI336327B (en) 2011-01-21
BRPI0317717B1 (pt) 2017-12-19
DE60315892D1 (de) 2007-10-04
PL412704A1 (pl) 2015-10-12
NO20052855D0 (no) 2005-06-13
AU2003290313A1 (en) 2004-07-22
DK1578755T3 (da) 2007-11-12
ATE370958T1 (de) 2007-09-15
NO335193B1 (no) 2014-10-20
AU2003290313B2 (en) 2007-05-10
RU2007121850A (ru) 2008-12-20
NO20052855L (no) 2005-08-03
CY1107775T1 (el) 2013-06-19
PL221490B1 (pl) 2016-04-29
KR101010299B1 (ko) 2011-01-25
RU2357971C2 (ru) 2009-06-10
ES2329623T3 (es) 2009-11-27
DK1847539T3 (da) 2009-11-09
JP4906608B2 (ja) 2012-03-28
IL185176A (en) 2011-10-31
SA04240504B1 (ar) 2008-04-01
PT1578755E (pt) 2007-10-19
JP2007326862A (ja) 2007-12-20
JP2006512418A (ja) 2006-04-13
US9567358B2 (en) 2017-02-14
WO2004058781A1 (en) 2004-07-15
EP1578755B1 (en) 2007-08-22
PT1847539E (pt) 2009-10-06
UY28149A1 (es) 2004-07-30
CA2511613C (en) 2012-10-02
KR20050088333A (ko) 2005-09-05
EP1847539B1 (en) 2009-08-05
ES2290529T3 (es) 2008-02-16
ATE438644T1 (de) 2009-08-15
JP2009046514A (ja) 2009-03-05
RU2005123485A (ru) 2006-03-10
CL2003002731A1 (es) 2005-01-07
EP1578755A1 (en) 2005-09-28
IS2884B (is) 2014-06-15
CA2511613A1 (en) 2004-07-15
PL223998B1 (pl) 2016-11-30
MXPA05006918A (es) 2005-08-18
IL169112A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
IL169112A (en) Phosphonooxy quinazoline derivatives and their pharmaceutical use
IL170758A0 (en) 7-amino-isoindolyl compounds and their pharmaceutical uses
PL378135A1 (pl) 2-Cyjanopirolopirymidyny i ich zastosowania w farmaceutykach
GB0215823D0 (en) Quinazoline derivatives
IL165986A0 (en) Isoquinoline and quinazoline derivatives and pharmaceutical compositions containing the same
EP1479666A4 (en) ESTER CONNECTION AND THEIR MEDICAL USE
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
IL172937A0 (en) Pyrimidine derivatives and pharmaceutical compositions containing the same
AU2003235956A1 (en) Quinazoline derivative and medicine
AU2002950853A0 (en) Aminopyrimidine compound and pharmaceutical use thereof
IL149377A0 (en) Pharmaceutical formulation comprising melatonin
GB2410025B (en) Quinazolin-4-one derivatives
GB0207410D0 (en) Compounds and their therapeutic use
IL172087A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
EP1541174A4 (en) MEDICINE OR COSMETIC PRODUCT
GB0206505D0 (en) Pharmaceutical combination
ZA200504997B (en) Phosphonooxy quinazolin derivatives and their pharmaceutical use
PL374817A1 (pl) Pochodne chinazoliny
PL373409A1 (pl) Kombinacja farmaceutyczna
GB0201520D0 (en) Pharmaceutical uses
AU2003264474A8 (en) Novel uracil derivatives and medicinal use thereof
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
EP1499338A4 (en) 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSENES-17-ONE AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONE AND THEIR DERIVATIVES
AU2003238900A8 (en) Pharmaceutical formulation
GB0328255D0 (en) Quinazoline derivatives and their uses